More News, and Considerations, on OncotypeDx
This week I’ve been reading about new developments in breast cancer (BC) pathology. At one level, progress is remarkable. In the 20 years since I began my oncology fellowship, BC science has advanced...
View ArticleNews, and Thoughts, on Comparative Effectiveness Research
Last week the U.S. Government Accountability Office (GAO) appointed several new members to the board of the Patient-Centered Outcomes Research Institute (PCORI). This group will oversee the application...
View ArticleConsidering Evidence for a New Drug for Immune Thrombocytopenia Purpura
I’ve been wondering, lately, why so many of the medical blogs cover the same topics, like last week’s lung cancer detection trial, which are often the exact same studies as are reported by conventional...
View ArticlePatients’ Words, Unfiltered, Medical Journalism and Evidence
Yesterday’s post was not really about Avastin, but about medical journalism and how patients’ voices are handled by the media. L. Husten, writing on a Forbes blog, cried that the press fawned,...
View ArticleFinal Word on Avastin, and Why We Need Better Physicians
Today’s breaking breast cancer news is on Avastin. The FDA has just announced, formally, that it will rescind approval for the drug’s use in people with metastatic breast cancer. Commissioner Dr....
View Article